The US FDA's benefit/risk assessment framework effectively explains agency approval decisions on new drug and biological applications and is useful for product sponsors in their drug development programs, but the agency should take steps to expand their use and increase their availability, a consultant's report concludes.
"The benefit/risk framework was successful in communicating the reasoning behind FDA's regulatory decisions, useful and worthwhile to various audiences, and...








